The drug maker has received final approval by the United States Food & Drug Administration (USFDA) for sirolimus tablets.
Sirolimus tablets are generic version of rapamune tablets of PF Prism CV. According to IQVIA sales data for the 12 month period ending August 2020, rapamune tablets achieved annual sales of approximately $119.7 million.
Glenmark Pharmaceuticals' current portfolio consists of 165 products authorized for distribution in the US marketplace and 45 Abbreviated New Drug Application (ANDA)'s pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals declined 1.45% to Rs 483.75. It jumped 3.46% at Rs 490.85 in the previous session.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across generics, specialty and OTC business with operations in over 50 countries. Its consolidated net profit surged to Rs 254.04 crore in Q1 June 2020 from Rs 109.28 crore in Q1 June 2019.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU